Introduction {#S1}
============

Autophagy at a Glance {#S1.SS1}
---------------------

The term autophagy is used to describe the lysosomal degradation of cytosolic material, a highly conserved process. It encompasses three distinct but related types: macroautophagy, microautophagy and chaperone-mediated autophagy (CMA). Macroautophagy involves the sequestration of cytoplasmic components (including organelles) into a double-membrane structure known as autophagosome, which eventually fuses with late endosomes and lysosomes for subsequent breakdown of its cargo. Microautophagy involves the direct engulfment of cellular components by invaginations of the lysosomes. Finally, CMA involves the recognition and capture of cytosolic components by Hsc70 chaperones and the subsequent translocation of these components into the lysosomal lumen ([@B44]; [@B57]).

Autophagy can act as a means for the cell to redistribute valuable nutrients in conditions of starvation; this is the case of bulk autophagy, which generally targets random parts of the cytosol. It can also act as a means to dispose of excessive or damaged organelles or invading microbes; this is the case of selective autophagy that involves the degradation of specific organelles such as the nucleus, mitochondria, peroxisomes, and often relies on specialized receptors and regulatory pathways to achieve that specificity ([@B57]).

Lipophagy as a Subset of Autophagy {#S1.SS2}
----------------------------------

Lipid droplets (LDs) are eukaryotic organelles responsible for the storage of lipids in the forms of triacylglycerols (TAGs), cholesteryl esters and retinyl esters surrounded by a phospholipid monolayer. The surface of the droplets is also coated with proteins, such as the perilipins; these are a family of five proteins that contribute to lipid droplet packing and regulate interactions with other organelles, droplet size, and accessibility to lipolytic mechanisms. Other LD proteins include enzymes involved in triacylglycerol and phospholipid synthesis or lipid transporters. The size of LDs can be quite varied, ranging from 1 μm in the majority of cell types to 100 μm in white adipocytes ([@B45]; [@B41]; [@B55]; [@B24]).

Lipid droplets allow for the storage of lipids that can be utilized for energy production as well as the synthesis of membrane components, signaling ligands and other special macromolecules. Such lipid storage protects the cells from exposure to excessive amounts of free fatty acids (FFAs) and sterols that can be damaging to cellular membrane composition, signaling pathways and metabolic homeostasis ([@B55]; [@B24]). The lipids can be accessed when needed through the process of lipolysis, which involves the breakdown of TAGs and esters by cytosolic lipases, such as Adipose Triglyceride Lipase (ATGL) ([@B94]; [@B49]; [@B48]).

In addition to lipolysis, lipid stores can also be accessed via lipophagy, a specific subset of selective autophagy that targets LDs and catabolizes their components into FFAs and glycerol. It was discovered in 2009 in a study that demonstrated clear co-localization of autophagic and LD markers, in conjunction with a necessity of autophagy for LD and triglyceride (TG) clearance in hepatocytes, both *in vitro* and *in vivo* ([@B70]).

In this review, we provide a brief summary of the existing knowledge on the mechanisms and regulation of lipophagy, as well as its functional importance in normal aging and disease.

Mechanisms and Regulation of Lipophagy {#S1.SS3}
--------------------------------------

Lipophagy, as any form of selective autophagy, primarily begins with the recognition of the cargo by the autophagosomal membrane through interaction with microtubule- associated protein 1 light chain 3 (MAP1LC3), which is a mammalian homolog of yeast Atg8 and a core component of the phagophore) ([@B43]). This typically involves the assistance of one or more cargo adaptors such as p62, Optineurin, NBR1 and NDP52 that connect the organelle membrane with LC3, and may require polyubiquitination of proteins on the organelle surface as a recruiting signal ([@B57]). The exact proteins facilitating these steps of LD recognition are not entirely known, but some clues exist: Huntingtin has been shown to be necessary for lipophagy under stress conditions, and seems to act by connecting p62 with LC3-II as well as releasing the pro-autophagic kinase ULK-1 from mTOR inhibition ([@B59]). Ancient Ubiquitous Protein 1 (AUP1) is a factor that localizes to LDs and acts as a recruiter for the E2 ubiquitin conjugase G2 ([@B72]). Proteins of the Rab molecular switch family may also play a part in this process, as many of them have been detected on LDs ([@B25]) and some have been associated with autophagy regulation; in particular, Rab7 ([@B62]), Rab10 ([@B33]), and Rab25 ([@B91]) have been shown to be indispensable for lipophagy in hepatocytes under certain conditions. The cytosolic lipolysis associated lipase ATGL, (also known as PNPLA2) has been shown to be a necessary and sufficient positive regulator of lipophagy induction in mice livers (acting through the deacetylase SIRT1), suggesting tight co-ordination between two lipolytic pathways. ATGL cannot facilitate LD catabolism without lipophagy and possesses LIR motifs (LC3-II interaction motifs) that are needed for its recruitment on LDs and the initiation of lipolysis ([@B42]; [@B61]). Another lipase of the same family, PNPLA8, can also interact with LC3 and induce lipophagy as part of a SREBP-2 response in a high fat diet mouse model ([@B23]). PNPLA3 is needed for lipophagy in starved human hepatocytes ([@B47]). PNPLA5 has also been shown to contribute to the autophagy of LDs as well as autophagic proteolysis and mitophagy ([@B13]). In addition to their potential role in LD recognition, all these lipases might contribute to lipophagy initiation by directly contributing to autophagosome formation via the mobilization of triglycerides and steryl esters ([@B69]; [@B77]).

Depending on their size, LDs can be targeted either by macroautophagy, in which an entire small LD is trapped in an autophagosome and consumed as a whole, or by the so-called piecemeal microautophagy, in which the autophagosomes sequester only parts of a large droplet, which then pinches off as a double-membrane vesicle enriched in LC3 for gradual consumption ([@B70]). Either way, upon lysosomal engulfment, the contents of the LD are broken down by special lipases known as lysosomal acid lipases (LALs) that are capable of catabolizing triacylglycerides, diacylglycerides, cholesteryl esters and retinyl esters ([@B78]; [@B68]; [@B16]; [@B64]). These lipases are notably different from their cytosolic counterparts because of their ability to function in an acidic (pH = 4, 5-5) rather than neutral (pH = ∼7) environment ([@B86]). It is worth noting that since, as mentioned previously, LDs are coated with perilipins, these proteins need to be removed before LD degradation by autophagy or even cytosolic lipases can occur. There is evidence indicating that this happens through chaperone-mediated autophagy of the perilipins themselves ([@B20]), a process regulated by AMPK signaling ([@B21]).

At the highest level, lipophagy (and general autophagy) is regulated by systems that sense and respond to the nutrient status of the cell, such as the nuclear receptors farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor alpha (PPARα), the transcriptional activator cAMP response element-binding protein (CREB) ([@B30]; [@B66]), mTOR ([@B29]; [@B34]; [@B89]) and AMPK ([@B65]; [@B32]). These systems control downstream factors in order to ensure that the levels of FFAs in the cells match their energy requirements. Generally, nutrient abundance inhibits lipophagy, while deprivation promotes it ([Figure 1](#F1){ref-type="fig"}). Conditions that demand higher energy expenditure, such as the deregulation of RNA polymerase III, can also have an inducing effect ([@B3]; [@B79]). Lipophagy can also act as a defensive mechanism against lipotoxicity. For instance, it is upregulated in models of SOCE (Store-Operated Calcium Entry) deficiency that exhibit reduced levels of cytosolic lipolysis. In this case, lipophagy is indispensible for cell survival ([@B43]).

![Under normal conditions, lipophagy is regulated by the nutrient status of the cell. Nutrient abundance inhibits lipophagy, since cells have no need for free fatty acids (FFAs) as an energy source. During periods of nutrient deprivation, on the other hand, lipophagy is activated to allow cells to tap into their fat reserves. The dashed line denotes reduced pathway functionality due to upstream inhibition.](fcell-07-00185-g001){#F1}

Expression of lipophagy-associated genes is primarily controlled by the master regulator of lysosomal biogenesis transcription factor EB (TFEB)/helix-loop-helix (HLH) -30; this factor has been shown to directly induce lysosomal lipase expression under starvation conditions in *Caenorhabditis elegans* and mice hepatocytes ([@B51]) and it is required for LD clearance in multiple systems ([@B51]; [@B67]). Other factors that have been linked to lipophagy regulation are TFE3, which can induce lipophagy in hepatocytes ([@B80]) and the forkhead homeobox transcription factor FOXO1, which is involved in lysosomal lipase and lipophagy induction in murine adipocytes under nutrient restricted conditions ([@B31]). FOXO1 is also needed for lipophagy in hepatocytes, in conjunction with FOXO3 and FOXO4 ([@B81]).

The Significance of Lipophagy {#S2}
=============================

Lipophagy and Aging {#S2.SS1}
-------------------

Experiments in *C. elegans* have shown that HLH-30/TFEB- mediated autophagy is a critical component of long lived phenotypes ([@B28]) and that the induction of lysosomal lipases can have a positive effect on organismal lifespan ([@B51]). LIPL-4, in particular, is a lipase that is necessary for longevity in germline-less worms, and whose overexpression extends lifespan in an autophagy dependent fashion ([@B29]). It seems that it does not actively participate in lipophagy, but may induce it by causing an enrichment of ω-3/6 polyunsaturated fatty acids ([@B50]). Downstream of LIPL-4 lies a signaling cascade in which a free fatty acid, oleoylethanolamide (OEA), activates nuclear receptors NHR-49 and NHR-80 to promote longevity ([@B14]).

Lipophagy and Disease {#S2.SS2}
---------------------

### Alcoholic Fatty Liver Disease {#S2.SS2.SSS1}

Alcoholic fatty liver disease (AFLD) refers to the damage caused to the liver by excessive consumption of alcohol. The symptoms include oxidative stress, lipid droplet accumulation in the cytoplasm of hepatocytes, mitochondrial damage and cell death ([@B9]). In particular, steatosis (excessive LD deposition) is an extremely common symptom of alcohol abuse ([@B52]). There are very few options for treatment of this disease and, despite the excessive research done to understand its pathophysiology, there is no therapy available and the treatment remains almost the same as 50 years ago ([@B71]). AFLD is a multifactorial disease that involves interactions between lipid metabolism, the immune system and oxidative stress ([@B37]). Alcohol oxidation in the liver induces lipid accumulation by shifting the cells redox potential from fatty acid β-oxidation to reductive synthesis. It also transcriptionally induces lipogenic enzyme expression and promotes import from fatty acid transporters ([@B85]). It has been found that, upon short-term supplementation, ethanol induces mitophagy and lipophagy in hepatocytes, which likely act as repair mechanisms against damage caused to mitochondria and steatosis ([@B8]). Ethanol-mediated mitochondrial damage leads to an increase in intracellular ROS, which can induce autophagy through Beclin-1 as a means to combat oxidative damage ([@B75]). Nonetheless, chronic alcohol exposure causes an impairment of autophagy and lipophagy ([@B10], [@B11]; [@B8], [@B9]; [@B63]; [@B5]). This impairment is most likely caused by activation of mTOR signaling and a reduction of lysosomal biogenesis in mice hepatocytes. Administration of the mTOR inhibitor Torin-1 to these mice restores lysosomal biogenesis and decreases steatosis and liver damage ([@B5]). Induction of autophagy with resveratrol in mice or HepG2 cell lines was similarly beneficial ([@B75]). In conclusion, lipophagy acts as a defensive mechanism against AFLD but cannot exert its protective activity for long as it is inhibited by chronic alcohol consumption ([Figure 2](#F2){ref-type="fig"}).

![The role of lipophagy in AFLD. Under acute ethanol (EtOH) exposure, lipophagy acts as a defense mechanism against lipid peroxidation, protecting hepatocytes. Under chronic exposure however, lipophagy is inhibited by mTOR and can no longer provide this protection. See text for more details. Dashed lines denote reduced pathway functionality due to upstream inhibition.](fcell-07-00185-g002){#F2}

### Non-alcoholic Fatty Liver Disease {#S2.SS2.SSS2}

Non-alcoholic fatty liver disease (NAFLD) is an umbrella term used for numerous liver- related conditions characterized by the accumulation of triglycerides in hepatocytes that is caused by an upregulation of free fatty acid levels and lipogenesis ([@B1]). NAFLD generally involves insulin resistance and the redirection of glucose from glycogen synthesis to lipogenesis ([@B60]; [@B19]). It has been associated with mutations in various lipid metabolism genes, such as patatin-like phospholipase domain-containing-3 (PNPLA3) ([@B58]), transmembrane 6 superfamily member 2 (TM6SF2) ([@B40]), membrane bound O-acyltransferase domain containing 7 (MBOAT7) ([@B39]) and multiple apolipoprotein C3 (ApoC3) gene variants ([@B54]; [@B53]; [@B88]). It has also been associated with mutations in autophagy-related genes. One such case is a deletion in the immunity-related GTPase family M (IRGM) gene that inhibits autophagic flux and increases LD availability in HepG2 and PLC/PRF/5 cells. This phenotype can be rescued via treatment with the autophagy inducer rapamycin ([@B35]). Superoxide dismutase 1 (SOD1) knock out mice exhibit low visceral fat and an increase of liver LDs during fasting that results in liver damage. Lipophagy is impaired in this model, with p62 accumulating on LDs but failing to complete the process ([@B27]). Sterol regulatory element-binding protein 2 (SREBP-2) is observed to be activated unconventionally to promote excessive cholesterol accumulation in NAFLD. Inhibition of SREBP-2 activity in cell and mouse models of NAFLD upregulated expression of autophagic markers, ultimately reducing lipid deposition ([@B7]). Induction of autophagy by FGF21 supplementation was successful in treating the NAFLD phenotype in fat-loaded HepG2 cells ([@B93]). Knock down of Rubicon, an autophagy suppressor that is increased in NAFLD patients, via siRNA in HepG2 cells, BNL-CL2 cells, and murine primary hepatocytes attenuated autophagy impairment and reduced endoplasmic reticulum stress, apoptosis and lipid accumulation in NAFLD inducing conditions. These positive effects were replicated in Rubicon KO mice ([@B74]). Recently, it was shown that serum methionine levels were abnormally increased in human NAFLD patients. Moreover, autophagy and lipophagy were impaired in hepatocytes from glycine *N*-methyltransferase (GNMT) -KO mice. Interestingly, a methionine deficient diet could rescue liver steatosis and restore autophagy levels to normal in GNMT-KO mice ([@B95]). All in all, the majority of studies indicate that lipophagy counteracts the progression of NAFLD, but is abnormally inhibited in some instances of the disease. However, it is worth noting that there is one study suggesting otherwise, as it showed that suppression of autophagy through inhibition of c-Jun N-terminal Kinase (JNK) attenuates insulin resistance in a NAFLD rat model ([@B82]).

### Liver Fibrosis {#S2.SS2.SSS3}

The term liver fibrosis is used to describe the common pathways of chronic or iterative damage that can be afflicted onto the liver by toxic factors, viral infections, autoimmune conditions, or metabolic and aging aspects ([@B4]). Progression of the disease leads to the emergence of liver fiber nodules and the disruption of liver structure and function by excessive deposition of extracellular matrix (ECM) components ([@B90]). Hepatic stellate cell (HSC) activation plays a pivotal role in this process by secreting fibrogenic factors that promote the production of collagen and the propagation of fibrosis ([@B87]). Contrary to the previously mentioned diseases, evidence shows that lipophagy fuels fibrosis in the liver and potentially other tissues. Characteristic marks of HSC activation include the release of extracellular lipid droplet contents, endoplasmic reticulum stress, oxidative stress, overexpression of G proteins and accumulation of p62. Interestingly, lipid droplet accumulation or inhibition of mitochondrial fatty acid β-oxidation inhibits fibrosis ([@B17], [@B18]; [@B22]). Blockage of autophagy through RNA interference or bafilomycin A1 reduced fibrogenesis and ECM accumulation in mouse and human HSC lines ([@B76]; [@B17]). Lipophagy in HSCs has been shown to be partially mediated through Rab25in a ROS dependent manner. Antioxidants, such as glutathione and N-acetyl cysteine, were effective in halting autophagy, suggesting a potential therapeutic approach ([@B91]).

### Lipophagy and Cancer {#S2.SS2.SSS4}

Tumors grow in a unique microenvironment with insufficient supply of oxygen and nutrients. Survival in such an environment requires metabolic reprogramming. A significant part of this reprogramming involves changes in lipid metabolism, with aggressive tumors exhibiting increased acquisition, production and storage of lipids and lipoproteins. Fatty acid β-oxidation provides a significant source of energy for tumors and is the dominant bioenergetic pathway for non-glycolytic tumors ([@B2]). Autophagy has been shown to have both pro-and anti-cancer roles. For instance, it can be anti-oncogenic by inhibiting inflammation or pro-oncogenic by protecting tumor cells from ROS damage due to hypoxic stress and preventing necrotic cell death ([@B6]; [@B84]).

Similarly, lipophagy can also have a dual role in cancer growth. On the one hand, lipophagy contributes to the mobilization of stored lipid content, allowing tumor cells to access a supply of energy that can be critical to their growth ([@B15]). CCAAT enhancer binding protein α (C/EBPα), a protein that is upregulated in hepatocellular carcinoma (HCC) patients, promotes resistance to energy starvation and carcinogenesis through lipophagy ([@B38]). On the other hand, lipophagy has been shown to act against tumorigenesis. Lysosomal acid lipase (LAL), the lipase that facilitates lipophagy, has been found to exhibit tumor suppressor activity, as its deficiency permits cancer growth and metastasis through the mTOR dependent activation of myeloid-derived suppressor cells ([@B92]). Hepatocyte specific expression of human LAL in otherwise LAL deficient mice was sufficient to inhibit B16 melanoma metastasis in the liver and lung ([@B12]). Lipophagy has also been shown to cause apoptosis in HeLa cells through the induction of endoplasmic reticulum and mitochondrial stress ([@B46]). Rab7, already mentioned as a lipophagy regulator, has been shown to have potential tumor suppressive properties and inhibit prostate tumor growth and invasion ([@B73]).

### Lipophagy in Obesity {#S2.SS2.SSS5}

A concrete link between lipophagy and obesity has still to be identified, although there are many indicators for such a relationship. Autophagy is generally downregulated in high fat diet models ([@B26]; [@B56]). Defective hepatic autophagy in obese mice induces insulin resistance through the promotion of endoplasmic reticulum stress. Restitution of autophagy through overexpression of Atg7 in these mice can restore insulin levels back to normal and improved glucose tolerance ([@B83]). In addition, deficiency of Bif-1, a membrane curvature promoting protein, can lead to the expansion of adipose mass, reduce the basal rate of adipose tissue lipolysis and induce obesity in mice. Bif-1 deficiency also reduces the abundance of autophagic-lysosomal proteins Atg9 and Lamp1 ([@B36]).

Conclusion {#S3}
==========

The field of lipophagy has yet to fully develop. Despite its infancy, it has already managed to provide significant new insights on lipid metabolism and energy homeostasis and represents a promising path forward to advance our understanding of lipid-associated disorders. Further research on the exact mechanisms of lipophagy regulation is certain to reveal valuable new targets for therapeutic approaches and improve our available toolset against obesity, liver disease and cancer.
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